SOUTH SAN FRANCISCO, Calif.,
Feb. 23, 2021 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today
announced that it will report its fourth quarter and year end 2020
financial results after market close on Tuesday, March 2, 2021. Rigel senior
management will follow the announcement with a live conference call
and webcast at 4:30pm Eastern Time
(1:30pm Pacific Time) to discuss the
financial results and give an update on the business.
Participants can access the live conference call by dialing
877-407-3088 (domestic) or 201-389-0927 (international). The
conference call and accompanying slides will also be webcast live
and can be accessed from the Investor Relations section of the
company's website at www.rigel.com. The webcast will be
archived and available for replay for 90 days after the call via
the Rigel website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with hematologic
disorders, cancer and rare immune diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate) tablets,
the only oral spleen tyrosine kinase (SYK) inhibitor, for the
treatment of adult patients with chronic immune thrombocytopenia
who have had an insufficient response to a previous
treatment. The product is also commercially available in
Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of
chronic immune thrombocytopenia in adult patients.
Fostamatinib is currently being studied in a Phase 3 trial
for the treatment of warm autoimmune hemolytic anemia
(wAIHA)1; an NIH/NHLBI-sponsored Phase 2 trial for the
treatment of hospitalized COVID-191 patients, in
collaboration with Inova Health System; and a Phase 2 trial for the
treatment of COVID-19 being conducted by Imperial College
London. Additionally, Rigel has launched a Phase 3
clinical trial of fostamatinib for the treatment of hospitalized
COVID-19 patients.
Rigel's other clinical programs include an interleukin
receptor-associated kinase (IRAK) inhibitor program and a
receptor-interacting serine/threonine-protein kinase (RIPK)
inhibitor program with partner Eli Lilly and Company. In addition,
Rigel has product candidates in clinical development with partners
AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.
Please see www.TAVALISSE.com for the full
Prescribing Information.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Investor Relations Contact:
Phone: 650.624.1232
Email: ir@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-2020-financial-results-and-business-update-301233101.html
SOURCE Rigel Pharmaceuticals, Inc.